28
Chapter 38 Macrolides, Lincomycins and Polymycins

Chapter 38 Macrolides, Lincomycins and Polymycins

Embed Size (px)

Citation preview

Page 1: Chapter 38 Macrolides, Lincomycins and Polymycins

Chapter 38

Macrolides, Lincomycins

and Polymycins

Page 2: Chapter 38 Macrolides, Lincomycins and Polymycins

大环内酯类药物 14元大环内酯类:红霉素、罗红霉素、克拉霉素、地红霉素

15元大环内酯类:阿奇霉素 16元大环内酯类:螺旋霉素、乙酰螺旋霉素、麦迪霉素、麦白霉素、罗他霉素、柱晶白霉素、交沙霉素、米欧卡霉素

Page 3: Chapter 38 Macrolides, Lincomycins and Polymycins

Macrolides

First generation : 1950’s—erythromycin Second generation : 1970’s—claithromycin

azithromycin Third generation :

Page 4: Chapter 38 Macrolides, Lincomycins and Polymycins

Common properties of Macrolides

Page 5: Chapter 38 Macrolides, Lincomycins and Polymycins

Antibacterial activity First generation

Most G+ organisms: pneumococci, streptococci, staphylococci , diphtheriae etc

Part G- organisms:legionella (军团菌) ,bacillus pertussis( 百日咳 ), brucella( 布氏 ) etc

Others: mycoplasma( 支原体 ), chlamydia trachomatis( 沙眼衣原体 ), rickettsia( 立克次体 ), spirochete ,anaerobes etc.

Second generation More active on G- organisms

Page 6: Chapter 38 Macrolides, Lincomycins and Polymycins

Mechanism of action Target

50s ribosomal RNA Mechanism

inhibition of translocation of mRNA

Page 7: Chapter 38 Macrolides, Lincomycins and Polymycins
Page 8: Chapter 38 Macrolides, Lincomycins and Polymycins
Page 9: Chapter 38 Macrolides, Lincomycins and Polymycins

Mechanism of resistance

Production of inactivating enzymes Modification of the ribosomal binding site Active efflux system MLSR

Page 10: Chapter 38 Macrolides, Lincomycins and Polymycins

Pharmokinetics

Absorption Erythromycin: not stable at acid pH New macrolides: stable po

Distribution Metabolism:

Erythromycin&clarithromycin: in liver Excretion

Erythromycin& azithromycin: bile Clarithromycin: kidney

Page 11: Chapter 38 Macrolides, Lincomycins and Polymycins

Commomly used macrolides

Page 12: Chapter 38 Macrolides, Lincomycins and Polymycins

Erythromycin

Antimicrobial activity Gram-positive organisms: pneumococci, stre

ptococci, staphylococci , diphtheriae etc Gram-negative organisms:legionella (军团菌) ,

bacillus pertussis( 百日咳 ), brucella( 布氏 ) ,

meningococci, diplococcus gonorrhoeae etc Others: mycoplasma( 支原体 ), chlamydia trach

omatis( 沙眼衣原体 ), rickettsia( 立克次体 ), spirochete ,anaerobes etc.

Page 13: Chapter 38 Macrolides, Lincomycins and Polymycins

Erythromycin

Clinical uses As penicillin substitute in penicillin-allergic or

resistant patients with infections caused by staphylococci, streptococci and pneumococci

Pertussis , diphtheriae Legionella and mycoplasma pneumonia H.p infection

Page 14: Chapter 38 Macrolides, Lincomycins and Polymycins

Erythromycin

Adverse reactions Gastrointestinal effects Liver toxicity Cardiotoxicity

Page 15: Chapter 38 Macrolides, Lincomycins and Polymycins

Erythromycin Erythromycin lactobionate( 乳糖酸红霉素) erythromycin estolate (无味红霉素 )

erythromycin stearate( 硬脂酸红霉素) erythromycin ethylsuccinate (琥乙红霉素, 利君沙)

Page 16: Chapter 38 Macrolides, Lincomycins and Polymycins

New macrolides antibiotics Advantage :

Broader spectrum, higher activity Orally effective High blood concentration Longer t 1/2

Less toxicity Mainly used in respiratory tract infection

Page 17: Chapter 38 Macrolides, Lincomycins and Polymycins

Clarithromycin (甲红霉素 , 克拉霉素)

Has the strongest activity on Gram-positive bacteria, legionella pneumophila, chlamydia pneumoniae and H.p

Good pharmacokinetic property Low toxicity

Page 18: Chapter 38 Macrolides, Lincomycins and Polymycins

Azithromycin ( 阿齐霉素 , 丽珠奇乐)

Has the strongest activity against mycoplasma pneumoniae (肺炎支原体)

More effective on Gram-negative bacteria Well tolerated T1/2 :35~48h once daily Mainly used in respitory tract infection

Page 19: Chapter 38 Macrolides, Lincomycins and Polymycins

Roxithromycin (罗红霉素,严迪) 1987 France The highest blood concentration F 72%~85% Respiratory tract infection and soft tissue

infection Low adverse effects

Page 20: Chapter 38 Macrolides, Lincomycins and Polymycins

Lincomycin and Clindamycin Antimicrobial activity

Gram-positive organisms Bacteroide fragilis and other anaerobes

Mechanism Binding to 50s ribosome subunit and inhibiting

protein synthesis Pharmacokinetics

Absorbed well Penetrate well into most tissues including bone

Page 21: Chapter 38 Macrolides, Lincomycins and Polymycins

Clindaycin

Clinical uses Severe anaerobic infection Acute or chronical suppurative osteomylitis , arthrit

is caused by susceptive organisms especially Staphylococci aureus

Adverse reactions Gastrointestinal effects: severe diarrhea and pseud

omembranous enterocolitis caused by Clostridium difficile :vancomycin & metronidazole

Other :Impaired liver function , neutropenia

Page 22: Chapter 38 Macrolides, Lincomycins and Polymycins

Polypeptide antibiotics

Vancomycin & TeicoplaninPolymyxinsbactitracin

Page 23: Chapter 38 Macrolides, Lincomycins and Polymycins

Vancomycin

Mechanism of action Inhibit cell wall synthesis

Antimicrobial spectrum: Narrow spectrum, active only against gram-positi

ve bacteria paticularly staphylococci Pharmacokinetics

Poorly absorbed from intestinal tract, iv Excreted from glomerular filtration 90%

Page 24: Chapter 38 Macrolides, Lincomycins and Polymycins

Vancomycin

Clinical uses Infection caused by MRSA, MRSE and penicillin-

resistant pneumococcus Treatment of antibiotic-associated enterocolitis ca

used by clostridium difficile po Adverse reaction

Ototoxicity & nephrotoxicity Red-man syndrome

Page 25: Chapter 38 Macrolides, Lincomycins and Polymycins

Teicoplanin

Similar to vancomycin in mechanism and antimicrobial spectrum

Can be given im as well as iv Less adverse reactions

Page 26: Chapter 38 Macrolides, Lincomycins and Polymycins

Polymyxins

Active only against gram-negative rods, particularly P.aeruginosa

Mechanism:increase permeability of cell membrane

Mainly used in P.aeruginosa infection when other drugs are resistant

Toxicity: nephrotoxicity & neurotoxicity

Page 27: Chapter 38 Macrolides, Lincomycins and Polymycins

Baciteracin

Active against gram-positive bacteria Inhibit cell wall formation No cross-resistance with other agents Topical use only because of nephrotoxicity

Page 28: Chapter 38 Macrolides, Lincomycins and Polymycins